Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03670680
Other study ID # 69HCL17_0266
Secondary ID 2017-A02017-46
Status Recruiting
Phase N/A
First received
Last updated
Start date October 16, 2018
Est. completion date October 16, 2025

Study information

Verified date January 2024
Source Hospices Civils de Lyon
Contact Géry LAMBLIN, MD
Phone 472 35 58 71
Email gery.lamblin@chu-lyon.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Menometrorrhagia is the first cause of consultation in gynecology. Etiology of menometrorrhagia is varied, but in majority of cases no underlying pathology is found, they are said functional idiopathic menometrorrhagia . In case of failure of medical treatment, for women who do not wish to preserve reproduction possibilities, a surgical treatment by endometrectomy (destruction of the uterine endometrial epithelial) can be proposed. Currently, a new system, Lina LibrataTM is available on the market. This system allows destructing endometrial membrane with a balloon which offer several advantages compared to present used system. Specially, it does not require dilatation of uterus's cervix and it reduces the pain. The investigator make hypothesis that the use of the system Lina LibrataTM does not cause pain and can be thus used under local anesthetic in ambulatory surgery. With the aim of developing ambulatory care, the main objective of this prospective monocentric study is to estimate the efficiency of Lina LibrataTM system in the treatment of functional idiopathic menometrorrhagia. Secondary objectives are to estimate the pain during the procedure, the rate of per and post-complications and quality of life.


Recruitment information / eligibility

Status Recruiting
Enrollment 38
Est. completion date October 16, 2025
Est. primary completion date October 16, 2025
Accepts healthy volunteers No
Gender Female
Age group 38 Years to 55 Years
Eligibility Inclusion Criteria: - Women from 40 to 50 years old - Not menopausal women - Do not want pregnancy - Having dysfunctional bleeding - informed and signed consent Exclusion Criteria: - Unacceptable postoperative risk disclosed on interview: coagulation disorder, immune disorder, evolutive disease, etc - Pregnancy or wish to have later pregnancy - Endometrium cancer (or suspicious of cancer) or precancerous conditions of the endometrium - Anatomical conditions (i-e history of caesarian, transmural myomectomy) or pathological conditions (i-e long term treatment) which can weaken myometrium - Genital or urinary infection at the time of the procedure - Intra uterine device - Pelvic inflammation - Inability to understand information provided - Not covered by a national health insurance scheme, prisoner or under administrative supervision

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Use of the Lina LibrataTM
Use of the Lina LibrataTM

Locations

Country Name City State
France Hospices Civils de Lyon Bron

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary rate of amenorrhea 4 weeks
Secondary pain score Pain at Hour 0 is assessed by VAS (Visual Analog Scale) rating from 0 to 10 (0=no pain). during surgery (Hour 0)
Secondary pain score Pain at Hour 2 is assessed by VAS (Visual Analog Scale) rating from 0 to 10 (0=no pain). 2 hours after surgery (Hour 2)
Secondary pain score Pain at Hour 6 is assessed by QDSA (Questionnaire de la Douleur Saint-Antoine). 6 hours after surgery (Hour 6)
Secondary pain score Pain at Hour 6 1 is assessed by VAS (Visual Analog Scale) rating from 0 to 10 (0=no pain).. 6 hours after surgery (Hour 6)
Secondary pain score Pain at Day 1 is assessed by QDSA (Questionnaire de la Douleur Saint-Antoine). the day after surgery (Day 1)
Secondary pain score Pain at Day 1 is assessed by VAS (Visual Analog Scale) rating from 0 to 10 (0=no pain). the day after surgery (Day 1)
Secondary pain score Pain at Day 7 is assessed by QDSA (Questionnaire de la Douleur Saint-Antoine) one week after surgery (Day 7)
Secondary pain score Pain at Day 7 is assessed by VAS (Visual Analog Scale) rating from 0 to 10 (0=no pain). one week after surgery (Day 7)
Secondary pain score Pain at Month 1 is assessed by QDSA (Questionnaire de la Douleur Saint-Antoine) one month after surgery (Month 1)
Secondary pain score Pain at Month 1 is assessed by VAS (Visual Analog Scale) rating from 0 to 10 (0=no pain). one month after surgery (Month 1)
Secondary recurrences of menorrhagia at month 1
Secondary recurrences of menorrhagia at month 6
Secondary assessment of menorrhagia on Higham's score Assessment by patients on Higham's score. A score greater than 100 points corresponds to bleeding greater than 80 ml of blood. 1 month after surgery
Secondary assessment of menorrhagia on Higham's score Assessment by patients on Higham's score. A score greater than 100 points corresponds to bleeding greater than 80 ml of blood. 6 months after surgery
Secondary evolution of hemoglobinemia hemoglobin measured by blood test 1 month after surgery
Secondary evolution of hemoglobinemia hemoglobin measured by blood test 6 months after surgery
Secondary per-operative complications per surgery day 0
Secondary post-operative complications post surgery day 0
Secondary measure of quality of life assessed by the questionnaire SF-12 (abridged version of the Medical Outcomes Study Short-Form General Health Survey SF-36). It allows to obtain 2 scores: mental and social score (from 5.89058 to 71.966825) and physical score (from 9.94738 to 70.02246). The average of this scores in the general population is 50. at month 1
Secondary measure of quality of life assessed by the questionnaire SF-12 (abridged version of the Medical Outcomes Study Short-Form General Health Survey SF-36). It allows to obtain 2 scores: mental and social score (from 5.89058 to 71.966825) and physical score (from 9.94738 to 70.02246). The average of this scores in the general population is 50. at month 6
Secondary measure of symptoms improvement assessed by the questionnaire PGI-I (from 1 "much better" to 7 "much worse") at month 1
Secondary measure of symptoms improvement assessed by the questionnaire PGI-I (from 1 "much better" to 7 "much worse") at month 6
See also
  Status Clinical Trial Phase
Completed NCT02824224 - Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS) Phase 4
Withdrawn NCT01651468 - The Effect of the Nutraceutical "Hemofix" on the Coagulation System N/A
Recruiting NCT02616731 - Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD Phase 1/Phase 2
Terminated NCT02087228 - Evaluation of the Endometrial Cavity After Endometrial Ablation N/A
Withdrawn NCT00953641 - Vaginal Misoprostol for Cervical Ripening Prior to Endometrial Biopsy Phase 3
Completed NCT01436903 - Chances for Success of CavatermTM Surgery as a Function of Uterus Probe Length Phase 4
Withdrawn NCT00768742 - Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study N/A
Completed NCT00156195 - Study to Evaluate the Safety of Asoprisnil in the Treatment of Uterine Fibroids Phase 3
Completed NCT00152256 - A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids Phase 3
Completed NCT00160381 - A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids Phase 3
Completed NCT02228174 - Sonography Guided Transcervical Ablation of Uterine Fibroids N/A
Terminated NCT01969396 - Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology N/A
Completed NCT00393198 - Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia Phase 4
Completed NCT00386308 - Efficacy and Safety Study of XP12B in Women With Menorrhagia Phase 3
Completed NCT00966264 - Hysterectomy and Levonorgestrel Releasing Intrauterine System (LNG-IUS) in the Treatment of Menorrhagia Phase 3
Completed NCT00904709 - The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders Phase 4
Completed NCT02584088 - Ultrasound Appearance of the Endometrium Post Radio-Frequency Ablation
Completed NCT02835391 - PerClot Compared to Usual Care in Gynaecology Procedures N/A
Completed NCT02304510 - Prevalence of Heavy Menstrual Bleeding in Female Population Living in Beijing
Completed NCT01197547 - Registry Study of Genesys HTA for Treatment of Menorrhagia N/A